Biohaven inks global Kv7 license with SK, secures up to $795M and royalties
Aug 26, 2026, 2:39 AM EDT2 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Non-dilutive cash improves BHVN's balance sheet; milestone upside and royalties provide optionality; a potential near-term catalyst from RISE3 results; leverages SK's commercial capabilities to de-risk Opakalim's path.
AI summary
What happened, with direct paths to the underlying reporting
Biohaven and SK Biopharmaceuticals announced a global licensing deal granting SK an exclusive worldwide license to Biohaven's Kv7 platform led by opakalim. The agreement delivers up to $795 million in upfront and milestone payments and tiered US royalties, providing non-dilutive capital while preserving long-term upside. RISE3 topline results due in 2H 2026 could serve as a near-term catalyst.
Biohaven and SK strike global Kv7 license; upfront/milestones up to $795M.
Royalties on US net sales expected in mid-teens to low-20s.
Opakalim in Phase 2/3; topline results due 2H 2026.
Non-dilutive funding strengthens Biohaven's balance sheet and runway.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Biohaven surged after the FDA accepted the Vyglxia (troriluzole) resubmission for spinocerebellar ataxia with a Q1 2027 user-fee goal. The agency stressed real-world evidence conc…
Biohaven and Ono Announced an exclusive Asia license for BHV-1300 and follow-ons, with up to $100 million in near-term payments and about 20% royalties on Ono's net sales in the t…
Biohaven said the U.S. FDA imposed a partial clinical hold on its epilepsy drug program, pausing new patient enrollment after rodent findings. Shares fell more than 13% in premark…
Biohaven announced two wins this week: a licensing agreement with SK Biopharmaceuticals and a legal victory with Yale University in a trade-secret dispute. The terms were not disc…